SOURCE: Deinove


June 10, 2013 08:48 ET

DEINOVE Today Announced Its Participation in Two Strategic Congresses to Be Held in North America

International Fuel Ethanol Expo, June 10-13, 2013, St Louis, MO, USA; Bio World Congress on Industrial Biotech, June 16-19, 2013, Montréal, Canada

PARIS--(Marketwired - Jun 10, 2013) - DEINOVE (Alternext Paris: ALDEI), a cleantech company that designs, develops and markets a new generation of industrial processes based on the Deinococcus bacteria, today announced its participation in two strategic congresses to be held in North America. These congresses will be the occasion to meet with new partners and exchange on the potential of the Deinococcus for new generation biofuels and other bio-based chemicals.

International Fuel Ethanol Workshop & Expo (FEW) June 10-13, 2013, St Louis, MO, USA

Now in its 29th year, the FEW provides the global ethanol industry with cutting-edge content and unparalleled networking opportunities in a dynamic business-to-business environment. The FEW is the largest, longest running ethanol conference in the world.

Emmanuel Petiot, CEO of DEINOVE, is on the panel of the roundtable in Track 4: Cellulosic & Advanced Ethanol, June 12, 2013, from 1:30pm to 3:00pm:
Emerging Approaches for Unlocking the Profit Potential of Cellulose: Emergence of a C6-C5 Bacterial Micro-Factory.

This roundtable will explore the potential for microorganisms to become true bacterial micro-factories for the production of cellulosic ethanol and biobased chemicals, as well as discuss opportunities for their integration in biorefineries at demonstration-scale.

Bio World Congress on Industrial Biotech, June 16-19, 2013, Montréal, Canada

The BIO World Congress on Industrial Biotechnology is the world's largest industrial biotechnology event for business leaders, investors, and policy makers in biofuels, biobased products, and renewable chemicals.

Emmanuel Petiot, CEO of DEINOVE, and Jean-Paul Léonetti, VP of R&D, will each take part in a breakout session designed to inform conferencees on cutting edge subjects within industrial biotechnology:

Jean-Paul Léonetti, Monday, June 17, 2013, from 2:30pm to 4:00pm:
Topic: Consolidated Bioprocessing of Lignocellulosic Feedstocks, Track 5: Synthetic Biology and Microbial Genomics.
Emmanuel Petiot, Wednesday, June 19, 2013, from 10:30am to 12:00pm:
Topic: Olefinic Synthetic Pathways and Biobased Products, Track 3: Renewable Chemical Platforms and Biobased Materials

Both panels will be the ideal opportunity for DEINOVE to highlight the key benefits of its synthetic biology platform applied to the Deinococci. Among other benefits: the ability to engineer new bacterial strains in an automated and robotic manner and the unique genomic stability of Deinococci and their capability to assimilate lignocellulosic biomass.


DEINOVE (Alternext Paris: ALDEI) is a cleantech company that designs and develops new standards of production based on bacteria of untapped potential: the Deinococci.

Taking advantage of their unique genetic properties and unusual robustness, DEINOVE optimizes natural fermentation and metabolic capabilities of these bacterial "micro-factories" to produce rare compounds or products that are technologically difficult to produce: 2nd generation biofuels (DEINOL) and chemical intermediates (DEINOCHEM), but also new antibiotics (DEINOBIOTICS project now led by the subsidiary DEINOBIOTICS SAS) or enzymes for the remediation of plastics (THANAPLAST™ project led by CARBIOS).

At the end of 2012, the Company obtained a first validation of the approach through DEINOL, a program supported by OSEO-ISI amounting to 8.9 million Euros, conducted in partnership with the sugar group TEREOS, French leader and the 2nd European producer of bioethanol. A DEINOVE bacterium turned wheat-based biomass into ethanol, without additives (enzymes, yeast, antibiotics or antiseptics), a world first.

Listed on Alternext since April 2010, DEINOVE was founded by Dr. Philippe Pouletty, General Partner of TRUFFLE CAPITAL, and Pr Miroslav Radman, of the Faculty of Medicine of the University René Descartes. It has a staff of about 30 people and conducts R&D programs in partnership with the CNRS (Marseille and Montpellier), INSA (Toulouse) and VTT (Finland). Headquarters and laboratories are located at DEINOVE Paris and the Technoparc Cap Alpha in Montpellier.
More information at


Contact Information